ERBB3 and non-small cell lung carcinoma: Among 82 NSCLC patients, no or low genomic gain for the HER3 gene (HER3−) was found in 73.2% of cases, whereas high polysomy and gene amplification (HER3+) was detected in 26.8% (Figure 1).